Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Bristol-Myers Squibb6,205 enrolled

Overview

The purpose of the study is to document real-world pattern of care, outcomes and health resource use for participants diagnosed with and receiving treatment for advanced Non-small cell lung cancer (NSCLC) and extensive disease Small cell lung cancer (SCLC) in China.

Study Type

OBSERVATIONAL

Enrollment

6,205

Conditions

Lung Cancer Non-small Cell Lung Cancer NSCLC Small Cell Lung Cancer SCLC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed advanced NSCLC (IIIB/IV) and extensive disease SCLC with pathology/cytology record between 1-Dec-2013 and 30-Nov-2014 * Received inpatient treatment more than twice (inclusive) at a selected site. For hospitals with outpatient records, patients receiving oral TKI therapy and routinely (more than twice a year) followed up outpatient will be included although no inpatient records. For hospitals with outpatient chemotherapy center, patients will be include if they were prescribed with chemotherapy and routinely (more than twice a year, inclusive) followed up outpatient in the hospital * 18 years of age or older at initial diagnosis of IIIB/IV NSCLC and extensive disease SCLC Exclusion Criteria: * Patients who have participated in or are attending clinical trials receiving active LC therapy * Unknown initial diagnosis time and initial treatment time. * For hospitals without outpatient chemo therapy center, patients who were prescribed with chemo therapy but with no inpatient records will be excluded * Patients who received inpatient therapy for one time and were not routinely (more than twice a year, inclusive) followed up outpatient will be excluded Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Shanghai, SHG, China

Outcomes

Primary Outcomes

Proportion of participants receiving first-line systemic therapy

Proportion of patients receiving first-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)

Time frame: Approximately 36 months

Proportion of participants receiving second-line systemic therapy

Proportion of patients receiving second-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)

Time frame: Approximately 36 months

Proportion of participants receiving third-line systemic therapy

Proportion of patients receiving third-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)

Time frame: Approximately 36 months

Proportion of participants receiving fourth-line systemic therapy

Proportion of patients receiving fourth-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)

Time frame: Approximately 36 months

Distribution of first-line regimens

All chemotherapy, radiation and/or biologic drugs given to a patient during the first 28 days after initiation of treatment

Time frame: Approximately 36 months

Distribution of subsequent regimens

All chemotherapy, radiation and/or biologic drugs given to a patient following first-line regimen

Time frame: Approximately 36 months

Distribution of first-line treatment duration

Calculated by the difference between the treatment start date of the first observed drug in the regimen and the last observed date of the regimen

Time frame: Approximately 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Distribution of patient demographic data

Time frame: At baseline

Distribution of disease characteristic data

Time frame: At baseline

Distribution of Overall Survival from first observed diagnosis to death

Time frame: At baseline

Distribution of Overall Survival from the initiation of first-line systemic anti-cancer therapy to death

Time frame: At baseline

Distribution of Overall Survival from the initiation of second-line systemic anti-cancer therapy to death

Time frame: At baseline

Distribution of Overall Survival from the initiation of third-line systemic anti-cancer therapy to death

Time frame: At baseline

Distribution of Overall Survival from the initiation of fourth-line systemic anti-cancer therapy to death

Time frame: At baseline

Distribution of other cancer-directed therapies

Distribution of other cancer-directed therapies including surgery and radiation as well as supportive care

Time frame: Approximately 36 months

Distribution of Interval of Therapy

Time frame: Up to 36 months

Distribution of Lung Cancer related direct health care costs

Time frame: Up to 36 months